Search Results
You are looking at 1 - 10 of 12 items for
- Author: X Wang x
- Refine by access: All content x
Search for other papers by N Sato in
Google Scholar
PubMed
Search for other papers by X Wang in
Google Scholar
PubMed
Search for other papers by M A Greer in
Google Scholar
PubMed
Abstract
The standard method of studying hormone secretion in vitro is to make instantaneous changes in the concentration of stimulators in the medium. However, in vivo the extracellular concentration of such substances changes more gradually; secretion does not occur in square-wave bursts and agonists or antagonists transmitted through the bloodstream are diluted and diffused by plasma or tissue fluid to further decelerate the rate of change in concentration at the cell surface. We have therefore compared in GH4C1 cells the dynamics of changes in cytosolic Ca2+ concentration ([Ca2+]i) and prolactin (PRL) secretion in response to two very different secretagogues, thyrotrophin-releasing hormone (TRH) and depolarizing K+, using a square-wave or ramp exposure for 5 min. The dynamics of hormone secretion were analysed by column perifusion (2 × 106 cells/column). Ca2+ dynamics were monitored by dual excitation microfluorimetry from 20–30 optically isolated cells using the Ca2+ indicator, fura-2. With square-wave exposure, both TRH (0·1–100 nm) and K+ (10–50 mm) induced dose-dependent increases in [Ca2+]i and PRL secretion. Concentrations of TRH >1 nm caused a two-phase increase in [Ca2+]i with an initial high-amplitude first phase and a low-amplitude second phase. Depolarizing K+ induced a sharp increase in [Ca2+]i which peaked within 15 seconds, then declined gradually on a sloping plateau. Both TRH and K+ induced an acute dose-dependent PRL secretory burst peaking within 2·5 min with a subsequent rapid decline. With ramp exposure, high doses of TRH (final concentration 10–100 nm) triggered an acute rise in [Ca2+]i; however, the peaks were clearly lower than those induced by the maximum concentration reached given as a square-wave. TRH (0·1–100 nm) induced PRL secretion in a dose-dependent manner. Ramp depolarizing K+ induced dose-dependent parallel 'ramp' increases in [Ca2+]i concentration and PRL secretion without a 'burst' rise in either. These data suggest that a rise in [Ca2+]i plays a more critical role in K+-induced than in TRH-induced PRL secretion; intracellular transduction systems which do not involve [Ca2+]i appear more important for the latter.
Journal of Endocrinology (1994) 142, 145–152
Search for other papers by X Wang in
Google Scholar
PubMed
Search for other papers by Day JR in
Google Scholar
PubMed
Search for other papers by Y Zhou in
Google Scholar
PubMed
Search for other papers by JL Beard in
Google Scholar
PubMed
Search for other papers by R Vasilatos-Younken in
Google Scholar
PubMed
Among the many responses to GH administration is suppression of voluntary feed intake (FI) in some species, attributed to improvement in the efficiency of nutrient utilization and, therefore, reduced need for ingested substrates. Commercial broiler chickens have been genetically selected for generations for rapid growth, realized largely via the major correlated response of increased voluntary feed consumption. Neuropeptide Y (NPY) and monoamines play very important roles in the central regulation of feeding. Preliminary studies from our laboratory suggest that the appetite-suppressive effect of GH may be independent of its actions as a repartitioning agent, and may involve alterations in NPY expression at the pre-translational level. The purpose of this investigation was to explore the dose-response nature of the appetite-suppressive effect of GH in juvenile broilers, and the possible involvement of NPY and monoamines in this process. A GH dose-response study was conducted using 8-week-old female broilers infused i.v. with GH in a pulsatile pattern for 7 days at 0, 10, 50, 100 or 200 microgram/kg body weight per day. Hypothalamic NPY and epinephrine (EP) concentrations decreased in a dose-related manner with GH. At the highest dosage, voluntary FI decreased 19% (P<0.05) and hypothalamic NPY mRNA decreased approximately 50% in the infundibular nuclei and midline region (P<0.0001). In contrast, birds pairfed to the high-GH dosage group did not differ from controls, verifying that changes in NPY and monoamines were not secondary to reduced FI. We conclude that hypothalamic NPY and EP are likely candidates to explore further as mediators of the appetite-suppressive effect of GH.
Search for other papers by H Tokuda in
Google Scholar
PubMed
Search for other papers by K Hirade in
Google Scholar
PubMed
Search for other papers by X Wang in
Google Scholar
PubMed
Search for other papers by Y Oiso in
Google Scholar
PubMed
Search for other papers by O Kozawa in
Google Scholar
PubMed
We previously reported that basic fibroblast growth factor (FGF-2) activates p44/p42 mitogen-activated protein (MAP) kinase resulting in the stimulation of vascular endothelial growth factor (VEGF) release in osteoblast-like MC3T3-E1 cells and that FGF-2-activated p38 MAP kinase negatively regulates VEGF release. In the present study, we investigated the involvement of stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in FGF-2-induced VEGF release in these cells. FGF-2 markedly induced the phosphorylation of SAPK/JNK. SP600125, an inhibitor of SAPK/JNK, markedly reduced the FGF-2-induced VEGF release. SP600125 suppressed the FGF-2-induced phosphorylation of SAPK/JNK without affecting the phosphorylation of p44/p42 MAP kinase or p38 MAP kinase induced by FGF-2. PD98059, an inhibitor of upstream kinase of p44/p42 MAP kinase, or SB203580, an inhibitor of p38 MAP kinase, failed to affect the FGF-2-induced phosphorylation of SAPK/JNK. A combination of SP600125 and SB203580 suppressed the FGF-2-stimulated VEGF release in an additive manner. These results strongly suggest that FGF-2 activates SAPK/JNK in osteoblasts, and that SAPK/JNK plays a part in FGF-2-induced VEGF release.
Search for other papers by X.-M. Wang in
Google Scholar
PubMed
Search for other papers by J. P. Coghlan in
Google Scholar
PubMed
Search for other papers by M. Congiu in
Google Scholar
PubMed
Search for other papers by B. A. Scoggins in
Google Scholar
PubMed
Search for other papers by E. M. Wintour in
Google Scholar
PubMed
ABSTRACT
The ability of opioid peptides to affect plasma immunoreactive ACTH concentrations was examined in conscious sheep. Plasma concentrations of ACTH were significantly increased by an i.v. infusion of Met-enkephalin and its analogue (FK-33824). There was a dose-dependent increase in plasma concentrations of ACTH with a graded administration of FK-33824. The combined effect of Met-enkephalin and ovine corticotrophin-releasing factor (oCRF) or FK-33824 and oCRF on plasma concentrations of ACTH was greater than the effect of each peptide when given individually. This study demonstrates that Met-enkephalin and its analogue stimulate ACTH release in sheep.
J. Endocr. (1986) 111, 463–467
Search for other papers by R.J. Bell in
Google Scholar
PubMed
Search for other papers by J.G. McDougall in
Google Scholar
PubMed
Search for other papers by X. Wang in
Google Scholar
PubMed
Search for other papers by E.M. Wintour in
Google Scholar
PubMed
ABSTRACT
Effects of maternal sodium depletion on the composition of ovine fetal fluids were studied. Maternal Na depletion was achieved by 48-h drainage of parotid saliva. There was a significant decrease in both maternal and fetal plasma Na concentration, indicating that both mother and fetus had experienced the Na-depletion stimulus. There was a significant increase in maternal blood aldosterone but the change in fetal blood aldosterone was not significant. In animals where there was an increase in fetal blood aldosterone the increase could be accounted for by transfer of aldosterone across the placenta from the mother. There was a significant decrease in fetal urinary Na concentration and Na excretion and the urinary Na/K ratio fell in seven out of eight studies. These observations are consistent with the hypothesis that fetal Na depletion sensitizes the fetal kidney to the action of circulating aldosterone as in the adult.
J. Endocr. (1985) 107, 177–182
Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources, Xiamen, China
Search for other papers by Cuili Wang in
Google Scholar
PubMed
Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources, Xiamen, China
Search for other papers by Dongteng Liu in
Google Scholar
PubMed
Search for other papers by Weiting Chen in
Google Scholar
PubMed
Search for other papers by Wei Ge in
Google Scholar
PubMed
Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources, Xiamen, China
Search for other papers by Wanshu Hong in
Google Scholar
PubMed
Department of Biology, East Carolina University, Greenville, North Carolina, USA
Search for other papers by Yong Zhu in
Google Scholar
PubMed
Fujian Collaborative Innovation Center for Exploitation and Utilization of Marine Biological Resources, Xiamen, China
State-Province Joint Engineering Laboratory of Marine Bioproducts and Technology, Xiamen University, Xiamen, China
Search for other papers by Shi X Chen in
Google Scholar
PubMed
Our previous study showed that the in vivo positive effects of 17α,20β-dihydroxy-4-pregnen-3-one (DHP), the major progestin in zebrafish, on early spermatogenesis was much stronger than the ex vivo ones, which may suggest an effect of DHP on the expression of gonadotropins. In our present study, we first observed that fshb and lhb mRNA levels in the pituitary of male adult zebrafish were greatly inhibited by 3 weeks exposure to 10nM estradiol (E2). However, an additional 24h 100nM DHP exposure not only reversed the E2-induced inhibition, but also significantly increased the expression of fshb and lhb mRNA. These stimulatory effects were also observed in male adult fish without E2 pretreatment, and a time course experiment showed that it took 24h for fshb and 12h for lhb to respond significantly. Because these stimulatory activities were partially antagonized by a nuclear progesterone receptor (Pgr) antagonist mifepristone, we generated a Pgr-knockout (pgr –/–) model using the TALEN technique. With and without DHP in vivo treatment, fshb and lhb mRNA levels of pgr –/– were significantly lower than those of pgr +/+. Furthermore, ex vivo treatment of pituitary fragments of pgr –/– with DHP stimulated lhb, but not fshb mRNA expression. Results from double-colored fluorescent in situ hybridization showed that pgr mRNA was expressed only in fshb-expressing cells. Taken together, our results indicated that DHP participated in the regulation of neuroendocrine control of reproduction in male zebrafish, and exerted a Pgr-mediated direct stimulatory effect on fshb mRNA at pituitary level.
Search for other papers by Xiwen Xiong in
Google Scholar
PubMed
Search for other papers by Xupeng Sun in
Google Scholar
PubMed
Search for other papers by Qingzhi Wang in
Google Scholar
PubMed
Search for other papers by Xinlai Qian in
Google Scholar
PubMed
Search for other papers by Yang Zhang in
Google Scholar
PubMed
Department of Endocrinology and Metabolism, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
Search for other papers by Xiaoyan Pan in
Google Scholar
PubMed
Search for other papers by X Charlie Dong in
Google Scholar
PubMed
Chronic exposure of pancreatic β-cells to abnormally elevated levels of free fatty acids can lead to β-cell dysfunction and even apoptosis, contributing to type 2 diabetes pathogenesis. In pancreatic β-cells, sirtuin 6 (SIRT6) has been shown to regulate insulin secretion in response to glucose stimulation. However, the roles played by SIRT6 in β-cells in response to lipotoxicity remain poorly understood. Our data indicated that SIRT6 protein and mRNA levels were reduced in islets from diabetic and aged mice. High concentrations of palmitate (PA) also led to a decrease in SIRT6 expression in MIN6 β-cells and resulted in cell dysfunction and apoptosis. Knockdown of Sirt6 caused an increase in cell apoptosis and impairment in insulin secretion in response to glucose in MIN6 cells even in the absence of PA exposure. Furthermore, overexpression of SIRT6 alleviated the palmitate-induced lipotoxicity with improved cell viability and increased glucose-stimulated insulin secretion. In summary, our data suggest that SIRT6 can protect against palmitate-induced β-cell dysfunction and apoptosis.
Search for other papers by C Y Shan in
Google Scholar
PubMed
Search for other papers by J H Yang in
Google Scholar
PubMed
Search for other papers by Y Kong in
Google Scholar
PubMed
Search for other papers by X Y Wang in
Google Scholar
PubMed
Search for other papers by M Y Zheng in
Google Scholar
PubMed
Search for other papers by Y G Xu in
Google Scholar
PubMed
Search for other papers by Y Wang in
Google Scholar
PubMed
Search for other papers by H Z Ren in
Google Scholar
PubMed
Search for other papers by B C Chang in
Google Scholar
PubMed
Search for other papers by L M Chen in
Google Scholar
PubMed
For centuries, Berberine has been used in the treatment of enteritis in China, and it is also known to have anti-hyperglycemic effects in type 2 diabetic patients. However, as Berberine is insoluble and rarely absorbed in gastrointestinal tract, the mechanism by which it works is unclear. We hypothesized that it may act locally by ameliorating intestinal barrier abnormalities and endotoxemia. A high-fat diet combined with low-dose streptozotocin was used to induce type 2 diabetes in male Sprague Dawley rats. Berberine (100 mg/kg) was administered by lavage to diabetic rats for 2 weeks and saline was given to controls. Hyperinsulinemia and insulin resistance improved in the Berberine group, although there was no significant decrease in blood glucose. Berberine treatment also led to a notable restoration of intestinal villi/mucosa structure and less infiltration of inflammatory cells, along with a decrease in plasma lipopolysaccharide (LPS) level. Tight junction protein zonula occludens 1 (ZO1) was also decreased in diabetic rats but was restored by Berberine treatment. Glutamine-induced glucagon-like peptide 2 (GLP2) secretion from ileal tissue decreased dramatically in the diabetic group but was restored by Berberine treatment. Fasting insulin, insulin resistance index, plasma LPS level, and ZO1 expression were significantly correlated with GLP2 level. In type 2 diabetic rats, Berberine treatment not only augments GLP2 secretion and improves diabetes but is also effective in repairing the damaged intestinal mucosa, restoring intestinal permeability, and improving endotoxemia. Whether these effects are mechanistically related will require further studies, but they certainly support the hypothesis that Berberine acts via modulation of intestinal function.
Search for other papers by E. M. Wintour in
Google Scholar
PubMed
Search for other papers by R. J. Bell in
Google Scholar
PubMed
Search for other papers by R. S. Carson in
Google Scholar
PubMed
Search for other papers by R. J. MacIsaac in
Google Scholar
PubMed
Search for other papers by G. W. Tregear in
Google Scholar
PubMed
Search for other papers by W. Vale in
Google Scholar
PubMed
Search for other papers by X.-M. Wang in
Google Scholar
PubMed
ABSTRACT
Synthetic ovine corticotrophin-releasing factor (oCRF) was infused continuously into the jugular veins of six ovine fetuses for 5–11 days. Two fetuses receiving 0·1 and 1·0 μg oCRF/h from gestational days 134 and 135 respectively, lambed prematurely on days 141 and 140 respectively. Three out of four fetuses receiving oCRF at 2·4 μg/h, from 125 days of gestation, delivered spontaneously at 131, 131 and 136 days, whilst one died in utero at 132 days. Two fetuses receiving vehicle only or oCRF intra-amniotically, were born at 148 and 145 days respectively, whilst six fetuses chronically cannulated but not infused were born at 149·8 ±2·1 (s.d.) days. In ewes lambing at term, maternal plasma progesterone concentrations were 41·4±11·4 (s.e.m.; n = 5), 28·8±7·8 (n = 6), 17·1 ±4·8 (n = 5) and 7·9± 1·1 (n = 4) nmol/l on 3, 2, 1 and 0 days respectively before the lambs were born. No such decrease in maternal plasma progesterone concentrations was seen in the oCRF-infused fetuses. Fetal plasma concentrations of immunoreactive ACTH were maintained above normal in oCRF-infused fetuses, but some desensitization to bolus oCRF injections occurred in these fetuses. Four of the five fetuses born prematurely were sufficiently mature to survive, being able to stand, breathe and suckle. It is concluded that continuous oCRF infusions into immature fetuses can accelerate maturation of a number of organs and systems culminating in the premature delivery of viable lambs.
J. Endocr. (1986) 111, 469–475
Search for other papers by R Vasilatos-Younken in
Google Scholar
PubMed
Search for other papers by Y Zhou in
Google Scholar
PubMed
Search for other papers by X Wang in
Google Scholar
PubMed
Search for other papers by JP McMurtry in
Google Scholar
PubMed
Search for other papers by RW Rosebrough in
Google Scholar
PubMed
Search for other papers by E Decuypere in
Google Scholar
PubMed
Search for other papers by N Buys in
Google Scholar
PubMed
Search for other papers by VM Darras in
Google Scholar
PubMed
Search for other papers by S Van Der Geyten in
Google Scholar
PubMed
Search for other papers by F Tomas in
Google Scholar
PubMed
In contrast to most vertebrates, GH reportedly has no effect upon somatic growth of the chicken. However, previous studies employed only one to two dosages of the hormone, and limited evidence exists of a hyperthyroid response that may confound its anabolic potential. This study evaluated the effects of 0, 10, 50, 100 and 200 microgram/kg body weight per day chicken GH (cGH) (0-200 GH) infused i.v. for 7 days in a pulsatile pattern to immature, growing broiler chickens (9-10 birds/dosage). Comprehensive profiles of thyroid hormone metabolism and measures of somatic growth were obtained. Overall (average) body weight gain was reduced 25% by GH, with a curvilinear, dose-dependent decrease in skeletal (breast) muscle mass that was maximal (12%) at 100 GH. This profile mirrored GH dose-dependent decreases in hepatic type III deiodinase (DIII) activity and increases in plasma tri-iodothyronine (T(3)), with bot! h also maximal (74 and 108% respectively) at 100 GH. No effect on type I deiodinase was observed. At the maximally effective dosage, hepatic DIII gene expression was reduced 44% versus controls. Despite dose-dependent, fold-increases in hepatic IGF-I protein content, circulating IGF-I was not altered with GH infusion, suggesting impairment of hepatic IGF-I release. Significant, GH dose-dependent increases in plasma non-esterified fatty acid and glucose, and overall decreases in triacylglycerides were also observed. At 200 GH, feed intake was significantly reduced (19%; P<0.05) versus controls; however, additional control birds pair-fed to this level did not exhibit any responses observed for GH-treated birds. The results of this study support a pathway by which GH impacts on thyroid hormone metabolism beginning at a pretranslational level, with reduced hepatic DIII gene expression, translating to reduced protein (enzyme) ex! pression, and reflected in a reduced level of peripheral T(3)-degrading activity. This contributes to decreased conversion of T(3) to its inactive form, thereby elevating circulating T(3) levels. The hyper-T(3) state leads to reduced net skeletal muscle deposition, and may impair release of GH-enhanced, hepatic IGF-I. In conclusion, GH has significant biological effects in the chicken, but profound metabolic actions predominate that may confound positive, IGF-I-mediated skeletal muscle growth.
